Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29394347 | 1.00 | MAPT (0.45) | MAPTALDH1A1GAARAB9ANPC1 | |
| SCHEMBL31456058 | 0.81 | LOXL2 (0.52) | MAPTALDH1A1GAARAB9ANPC1 | |
| SCHEMBL14399403 | 0.81 | MAPT (0.45) | MAPTALDH1A1GAARAB9ANPC1 | |
| SCHEMBL5380629 | 0.81 | CYP1A2 (0.47) | MAPTALDH1A1GAARAB9ANPC1 | |
| SCHEMBL15986775 | 0.81 | MAPT (0.45) | MAPTALDH1A1GAARAB9ANPC1 | |
| SCHEMBL1126175 | 0.81 | ADRA2A (0.49) | MAPTALDH1A1GAARAB9ANPC1 | |
| SCHEMBL3096453 | 0.81 | MAPT (0.45) | MAPTALDH1A1GAARAB9ANPC1 | |
| SCHEMBL28900871 | 0.79 | ADRA2A (0.47) | MAPTALDH1A1GAARAB9ANPC1 | |
| SCHEMBL8200767 | 0.78 | POLB (0.49) | MAPTALDH1A1GAARAB9ANPC1 | |
| SCHEMBL7075509 | 0.78 | CYP2C19 (0.48) | MAPTALDH1A1GAARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528781-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4192831-B1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20240376061-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2024-11-14 | — | — | US | disclosed |
| US-11897851-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| CN-116323599-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20230192633-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192633-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192633-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-06-22 | — | — | US | disclosed |
| EP-4192831-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| US-7449570-B2 | Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases | PTC THERAPEUTICS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20060166926-A1 | Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases | PTC THERAPEUTICS, INC. | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192633-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | MAPT 3959/4885ALDH1A1 1044/4885GAA 1010/4885 |
| US-11897851-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, GCGR | MAPT 3959/4885ALDH1A1 1044/4885GAA 1010/4885 |
| US-20060166926-A1 | Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases | NSUN2, UPF1, NSUN3 | MAPT 3685/4885ALDH1A1 2951/4885GAA 131/4885 |
| US-12528781-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, VIP | MAPT 3404/4885ALDH1A1 3780/4885GAA 1396/4885 |
| US-20240376061-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | MAPT 3959/4885ALDH1A1 1044/4885GAA 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.